Compare SIDU & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIDU | SLGL |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 243.4M | 254.1M |
| IPO Year | 2021 | 2016 |
| Metric | SIDU | SLGL |
|---|---|---|
| Price | $1.93 | $64.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $110.00 |
| AVG Volume (30 Days) | ★ 3.1M | 53.9K |
| Earning Date | 05-14-2026 | 05-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.94 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,383,878.00 | N/A |
| Revenue This Year | $171.29 | N/A |
| Revenue Next Year | N/A | $223.84 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.63 | $23.15 |
| 52 Week High | $6.79 | $97.97 |
| Indicator | SIDU | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.53 | 33.03 |
| Support Level | $1.73 | $64.78 |
| Resistance Level | $3.12 | $80.66 |
| Average True Range (ATR) | 0.11 | 4.06 |
| MACD | -0.03 | -0.73 |
| Stochastic Oscillator | 4.65 | 6.38 |
Sidus Space Inc is a space and defense technology company with core capabilities that include dual use satellite manufacturing & technology integration, AI products and services, space and defense hardware components and space-based data solutions. The company generates revenue through a combination of: Satellite platform sales and customization, Payload hosting and mission services, Engineering and systems integration services, and Space and defense hardware manufacturing. The firm supports Commercial Space, Aerospace, Defense, Underwater Marine, and other commercial and government customers. The firm generates revenue principally from satellite platform and payload hosting contracts, manufacturing and engineering services, mission operations, and sales of proprietary hardware products.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted. It generates the majority of its revenue from the United States.